Tirzepatide is a GLP-1 receptor agonist that
Semaglutide (Ozempic, Wegovy) mimics one hormone, GLP-1
Average Weight Loss: In one prominent clinical trial (SURPASS-2), patients taking Tirzepatide saw an average weight loss of around 15-20% of their body weight after 6 months of treatment.This result was significantly higher compared to other treatments for diabetes and weight loss
The question of whether tirzepatide causes bone loss is actively being studied
In the meantime, staying hydrated, eating smaller but well-balanced meals, and getting enough exercise and sleep can help
If you reconstitute with the wrong volume of water, your concentration will be different from what you expect, and every subsequent dose will be wrong